

49. Mitteilungsblatt

Nr. 57

Mitteilungsblatt der Medizinischen Universität Wien
Studienjahr 2025/2026
49. Stück; Nr. 57

Bevollmächtigungen

57. Bevollmächtigungen gem. § 27 Abs. 2 UG

57. Bevollmächtigungen gem. § 27 Abs. 2 UG

Gemäß § 27 Abs. 2 UG werden folgende Bevollmächtigungen erteilt:

Auftragsnummer	Projekttitlel	Organisationseinheit	Projektleiter(in)
FA731B2406	OPBC-10/NOAX:Axillary radiotherapy or axillary lymph node dissection in patients with clinically node-positive breast cancer undergoing upfront tailored axillary surgery: An international, randomized superiority trial"	Allgemeinchirurgie_731	Exner Ruth
FA731X0302	Kuerzere Liegedauer nach minimalinvasiver onkologischer Darmchirurgie	Allgemeinchirurgie_731	Unger Lukas
FA731B1006	A PHASE Ib/II, OPEN LABEL, MULTICENTER, RANDOMIZED PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT IMMUNOTHERAPY COMBINATIONS IN PATIENTS WITH SURGICALLY RESECTABLE HEPATOCELLULAR CARCINOMA (MORPHEUS NEO HCC) (Study) under Protocol No. GO44457 (Protocol)	Allgemeinchirurgie_731	Kaczirek Klaus
FA738A3401	Bridging Clinical Guidelines with Real-time Patient Data: An AI Knowledge Graph Framework for Anesthesia and Intensive Care	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Gonzalez Camila
FA738A3501	Association of anti-factor Xa activity with venous thromboembolism in critically ill patients: a prospective cohort study	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Dibiasi Christoph

FA738A3601	Waveform Adaptation, Visualization, Export & Standardization framework: toolkit for Analytics & Reuse	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Laxar Daniel
UE73806009	Exploring Sex and Gender in Statins' Effects on Arterial Stiffness: A Systematic Review	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Schluchter Helena
FW613A0701	Characterization of undiagnosed Austrian LGMD patients	Anatomie und Zellbiologie_310	Winter Lilli
FA746A3603	Temporary Tear Duct Filling with Hyaluronic Acid Gel and Assessment of Dry Eye Disease (DED) after Bilateral Cataract Surgery in a Prospective Randomised Controlled Inter-eye Study (TANAMI)	Augenheilkunde und Optometrie_746	Reiter Gregor Sebastian
FA746A4501	CATALINA-2: A Phase 2, Study Evaluating the Efficacy and Safety of TORL-1-23 In Women in Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6	Augenheilkunde und Optometrie_746	Mylonas Georgios
FA746A0323	Abbildungsqualität von EDof IOLs (Teil 2) (Through Focus Response und Through Focus MTF von EDof IOLs im klinisch relevanten Defokusbereich)	Augenheilkunde und Optometrie_746	Pieh Stefan
FA746A4601	ML44812 - Influence of Fluid Fluctuation on the Development of Fibrosis and Atrophy in nAMD under Intravitreal Faricimab Treatment mit dem zugelassenen Arzneimittel Vabysmo® (Faricimab)	Augenheilkunde und Optometrie_746	Bühl Wolf
FA746A1511	A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants with Metabolic Dysfunction-Associated Steatotic Liver Disease who are at Increased Risk of Developing Major	Augenheilkunde und Optometrie_746	Pollreisz Andreas

	Adverse Liver Outcomes (SYNERGY-Outcomes)		
FA746A4302	A Phase III, randomized, multi-site, open-label trial of BNT323/DB 1303 versus investigator's choice of chemotherapy in previously treated patients with HER2-expressing recurrent endometrial cancer	Augenheilkunde und Optometrie_746	Weigert Günther
FA746A4502	A two-part, seamless, multicenter, randomized, open-label, adaptive phase II/III study of the blood-brain barrier penetrant RO7771950 versus tucatinib, both in combination with trastuzumab and capecitabine, in patients with pretreated unresectable locally advanced or metastatic HER2-positive breast cancer, with or without central nervous system metastases	Augenheilkunde und Optometrie_746	Mylonas Georgios
FA746A0419	Post Market Clinical Follow-Up Study to demonstrate the Safety and Performance of the PRESERFLO MicroShunt XI in patients with primary open angle glaucoma	Augenheilkunde und Optometrie_746	Vass Clemens
FA746A4005	MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)	Augenheilkunde und Optometrie_746	Aschauer Julia
FA746A4503	Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects	Augenheilkunde und Optometrie_746	Mylonas Georgios

	with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETA-PDAC-288		
FA746A4303	A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First line Maintenance Therapy in HER2 Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144-O/GOG-3112)	Augenheilkunde und Optometrie_746	Weigert Günther
FA746A1665	A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMD)	Augenheilkunde und Optometrie_746	Sacu Stefan
FA746A4504	A randomized phase II Study to evaluate the safety and efficacy of trastuzumab deruxtecan versus CDK4/6 inhibitor-based endocrine therapy as first-line therapy of HR-positive and HER2-low/ultralow advanced breast cancer patients classified as non-luminal subtypes according to gene expression profiling (The PONTIAC Study)	Augenheilkunde und Optometrie_746	Mylonas Georgios
FA746A2807	A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects with Primary Non-metastatic Uveal Melanoma (OptimUM-10)	Augenheilkunde und Optometrie_746	Dunavölgyi Roman
FA662A0903	Effects of the HDAC6 Inhibitor, TN-301, on Cardiomyopathy in DMDmdx Rat Model	Biomedizinische Forschung und Translationale Chirurgie_308	Kiss Attila

FA662A1401	Neue Biomarker des kardinalen Remodellings: Tenascin-C im Fokus der hypertrophen Kardiomyopathie	Biomedizinische Forschung und Translationale Chirurgie_308	Pokreisz Peter
FA662A0803	Halb-automatisches Gerät zum Einbringen von Kanülen in Blutgefäße	Biomedizinische Forschung und Translationale Chirurgie_308	Schneider Karl
FA722A0209	Empowering Near-home Antimicrobial Resistance Diagnostics	Dermatologie_722	Sary Georg
FA722C1219	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants with Hereditary Angioedema - ALPHA-ORBIT	Dermatologie_722	Kinacian Tamar
FA722C1220	STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema	Dermatologie_722	Kinacian Tamar
FW722A0901	EPIC-CRC: Epigenetic reprogramming of the colorectal cancer tumor microenvironment to overcome immunotherapy resistance.	Dermatologie_722	Kusienicka Anna
FA722A2801	NAZARÉ: Concurrent optical and magnetic stimulation (COMS) for treatment of patients with chronic venous and arterial ulcers: A prospective randomized, controlled, assessor blinded, post-marketing clinical trial	Dermatologie_722	Deinsberger Julia
FA722B2324	Hautmodell AH - FO999939253	Dermatologie_722	Mildner Michael
FA722B2321	Hautmodell AH - FO999939254	Dermatologie_722	Mildner Michael
FA722B2322	Hautmodell AH - FO999939255	Dermatologie_722	Mildner Michael
FA722B2323	Hautmodell AH - FO999939294	Dermatologie_722	Mildner Michael

FA722B2319	Hautmodell KM - FO999939250	Dermatologie_722	Mildner Michael
FA722B2320	Hautmodell KM - FO999939251	Dermatologie_722	Mildner Michael
FA722A2802	Austrian Registry for Endovenous Ablation Techniques	Dermatologie_722	Deinsberger Julia
FA722A0703	The effect of anifrolumab on cutaneous lupus erythematosus characterized by the change of the inflammatory infiltrate analyzed by immunohistochemistry, spatial transcriptomics and single-cell RNA- and TCR- sequencing as well as on the clinical outcome - an open label, single arm phase IV pilot study	Dermatologie_722	Heil Peter
FA722A0804	MEndelian Randomisation for Evaluating Medicines and Approved Pharmacotherapies in ME/CFS	Dermatologie_722	Vincenzi Leonardo
FA722C1221	A Phase 3, Randomized, Double-blind, Placebo- controlled, 3-Part Study to Evaluate the Efficacy and Safety of Orally Administered Deucricitibant XR Tablet for Prophylaxis and Deucricitibant Soft Capsule for On-demand Treatment of Angioedema Attacks in Adults with Acquired Angioedema due to C1 Inhibitor Deficiency	Dermatologie_722	Kinaciyani Tamar
FA722A3001	Uncovering the Genetic Contribution of Human Endogenous Retroviruses to ME/CFS	Dermatologie_722	Gimenez Orenga Karen
FA722A3101	Decoding Early-Life UVA and Skincare Additive Interactions Driving Melanoma Risk and Progression in Young Adults	Dermatologie_722	Pfisterer Karin

FA751C1612	A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1	Frauenheilkunde_751	Polterauer Stephan
FA751C1613	A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer	Frauenheilkunde_751	Polterauer Stephan
FA751C2608	A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitug Samrotecan (AZD8205) Monotherapy versus Physicians Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy	Frauenheilkunde_751	Concin Nicole
FW751B0201	3D Models & Single-Cell Tools for Placental Angiogenesis	Frauenheilkunde_751	Haider Sandra
FA751B1101	The human microbiome in pROM, cervical insufficiency, preterm birth and the neonatal infant: a	Frauenheilkunde_751	Föbleitner Philipp

	prospective longitudinal pilot-study		
FA751C0688	Biobank-Projekt Establishment of a breast cancer serum-based biobank	Frauenheilkunde_751	Singer Christian
FA751C2701	Elektrische Aurikuläre Vagus-Nerv-Stimulation bei Frauen mit symptomatischer Endometriose; eine prospektive, doppelblinde, sham-kontrollierte, randomisierte Pilotstudie	Frauenheilkunde_751	Heine Jana
FA751D1601	Lipödem I	Frauenheilkunde_751	Bögl Magdalena Sophie
FA751D1602	Lipödem II	Frauenheilkunde_751	Bögl Magdalena Sophie
FA751C2610	A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced Non-HRD Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy	Frauenheilkunde_751	Concin Nicole
FA751B0110	Register über den Einfluss der assistierten Reproduktion auf die Schwangerschaft, das mütterliche und neonatale Outcome	Frauenheilkunde_751	Zeisler Harald
FA751C2611	FOLRalpha Heterogeneity in Epithelial Ovarian Cancer - A Translational Pilot Study	Frauenheilkunde_751	Concin Nicole
FA751C1614	A Two-Part Phase 3 Study of LY4170156 versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and LY4170156 plus Bevacizumab versus Platinum-Based Chemotherapy plus	Frauenheilkunde_751	Polterauer Stephan

	Bevacizumab in Platinum-Sensitive Ovarian Cancer		
UE75106008	CDG-Internship	Frauenheilkunde_751	Kiss Herbert
FA655A0101	Exploring natural selection due to the Black Death and continuous human population genetic structure	Gerichtsmedizin_304	Kanz Fabian
FA744B1801	A Phase 3, Open-Label, Multicenter, Randomized Study of a Combination of CBP501, Cisplatin and Nivolumab or Physicians Choice of Therapy for 3rd Line Treatment of Patients with Advanced Pancreatic Adenocarcinoma [FUJI-PanCo1]	Hals-, Nasen- und Ohrenheilkunde, Kopf- und Halschirurgie_744	Dahm Valerie
FA732A0205	TRAC-AF	Herz- und Thorakale Aortenchirurgie_732	Osorio Emilio
FA732A1401	Educational Grant	Herz- und Thorakale Aortenchirurgie_732	Dumfarth Julia
FA732A1601	Chirurgischer Bioprothesen-Aortenklappenersatz im Vergleich zur ballonexpandierbaren THV-Serie von Myval bei Patienten im Alter von 65 bis 75 Jahren mit symptomatischer schwerer Aortenstenose	Herz- und Thorakale Aortenchirurgie_732	Coti Iuliana
FA732A1501	A Two-Stage Ventricular Assist Device for Pediatric Patients	Herz- und Thorakale Aortenchirurgie_732	Wollmann Sarah
FA732A0807	Bewertung des Revaskularisationsentscheid ung bei unterrepräsentierten Patientengruppen (RECHARGE: Frauen-Studie)	Herz- und Thorakale Aortenchirurgie_732	Sandner Sigrid
FA732A0605	European Clinical Investigation of the BrioVAD Left Ventricular Assist System for the Treatment of Refractory Left Ventricular Heart Failure	Herz- und Thorakale Aortenchirurgie_732	Zimpfer Daniel

FA732A1701	Pospektiver WCD post CABG Register	Herz- und Thorakale Aorten Chirurgie_732	Schukro Christoph
FA732A0606	Registry to Assess the Safety and Feasibility of the Subpulmonary Support with the Novel Venous Cannula in Patients with Failing/Absence of the Right Heart	Herz- und Thorakale Aorten Chirurgie_732	Zimpfer Daniel
UE73206006	Forschungsförderung GIGAX Stiftung	Herz- und Thorakale Aorten Chirurgie_732	Zimpfer Daniel
FA732A1402	Educational Grant_FAME	Herz- und Thorakale Aorten Chirurgie_732	Dumfarth Julia
UE73206007	CDG Internship 2026	Herz- und Thorakale Aorten Chirurgie_732	Granegger Marcus
FA630A0301	Regulation of prosocial and cognitive behaviors along the dorsoventral hippocampal axis	Hirnforschung_360	Bauer Mikulovic Sanja
FA630A0202	Präklinische Machbarkeitsstudie zur AAV-basierten Gentherapie bei neuropathischen Schmerzen	Hirnforschung_360	Drdla-Schutting Ruth
FW620A0102	Prefrontal dynamics during value-based decision making	Hirnforschung_360	Klausberger Thomas
FA711C0973	eSMART, Save Haven - personalisierte telemedizinische Unterstützung von CAR T Zell Patienten / Creating Possible Award 2025	Innere Medizin I_711	Valent Peter
FA711B1080	Eine multizentrische, randomisierte, offene klinische Studie der Phase III zu Tislelizumab als subkutane Injektion im Vergleich zur intravenösen Infusion plus Chemotherapie als Erstlinienbehandlung bei Patienten mit lokal fortgeschrittenem, nicht resezierbarem oder metastasiertem Adenokarzinom des Magens oder gastroösophagealen Übergangs	Innere Medizin I_711	Preusser Matthias

FA711B1081	A non-interventional study for Kisqali (ribociclib) in combination with an aromatase inhibitor for adjuvant treatment in patients with HR+/HER2-early breast cancer at high risk of recurrence to evaluate real-world effectiveness, safety profile, patient compliance and quality of life (CAROLEEN)	Innere Medizin I_711	Preusser Matthias
FA711B1082	ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Punitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer	Innere Medizin I_711	Preusser Matthias
FA711A0324	Galectin-3-zielgerichtete antifungale Prophylaxe bei Influenza-Patienten auf der Intensivstation (GALActIC)	Innere Medizin I_711	Burgmann Heinz
UE71106020	Personalkostenersatz LBI für Julia Koschel von 01.01.2026 bis 31.12.2026	Innere Medizin I_711	Valent Peter
FW711A0101	Inflammatory Memory in Epithelia: organ imprint and cancer	Innere Medizin I_711	Starkl Philipp
FA711B1083	Europäisches Mantelzelllymphom Register (Manifestationen, Behandlungsdaten, Therapiesequenzen), (EMCL_Reg)	Innere Medizin I_711	Preusser Matthias
FA711B1084	CaboLife: A Prospective Non-Interventional Study On Effectiveness And Safety Of Cabozantinib In Real-Life Setting For Previously Treated Patients With Neuroendocrine Tumours	Innere Medizin I_711	Preusser Matthias
FA711C0975	Anwendungsbeobachtung nach der Zulassung von ELZONRIS(Tagraxofusp) bei Patienten mit blastischer plasmazytoider	Innere Medizin I_711	Valent Peter

	dendritischer Zellneoplasie (BPDCN)		
FA711C1428	Star VIVID-6_VGA039-CP002: A Prospective, Multicenter, Open-label, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Prophylactic VGA039 in Adolescent and Adult Patients with von Willebrand Disease (VIVID-6)	Innere Medizin I_711	Ay Cihan
FA711C0974	A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation	Innere Medizin I_711	Valent Peter
FA711B1085	A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamid Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy	Innere Medizin I_711	Preusser Matthias
FA711B1086	WO46069: Zweiteilige, nahtlose, multizentrische, randomisierte, offene, adaptive Studie der Phase II/III zur Prüfung von Blut-Hirn-Schranke-Gängigem RO7771950 im Vergleich zu Tucatinib, beide in Kombination mit Trastuzumab und Capecitabin bei Patient:innen mit vorbehandeltem, inoperablem, lokal fortgeschrittenem oder metastasiertem HER2-Positivem Mammakarzinom mit oder ohne Metastasen im Zentralnervensystem	Innere Medizin I_711	Preusser Matthias

FA711C1429	A Post-Authorization Safety Study (PASS) to Further Evaluate Real-World Safety in Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated with Adzynma, Takeda Protocol No. TAK-755-4007	Innere Medizin I_711	Ay Cihan
FA711B1087	A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head and Neck Cancer	Innere Medizin I_711	Preusser Matthias
FA711A0606	The Ticks and The Tock: Unravelling the Immune Battle at the Bite Site and Beyond.	Innere Medizin I_711	Starkl Philipp
FA711B1088	A Phase 2/3, multicenter, randomized open-label study of zanzalintinib versus everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors	Innere Medizin I_711	Preusser Matthias
FA711A0325	Phase 2 Trial to determine the safety and efficacy of simultaneous treatment with ruxolitinib and extracorporeal photopheresis for patients with steroid-refractory chronic Graft-versus-Host-Disease	Innere Medizin I_711	Burgmann Heinz
FA711A0326	Restrictive versus Liberal Thresholds for Red Blood Cell Transfusion in ExtraCorporeal Membrane Oxygenation - the TREC study	Innere Medizin I_711	Burgmann Heinz
FW711D0101	Check the BALance - ARDS deconvolution by bronchoalveolar lavage multiomics profiling and radiomics	Innere Medizin I_711	Gawish Riem
FA711Co976	Hämatologiekurs 2027	Innere Medizin I_711	Valent Peter

FA711B1089	A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects with Primary Non-metastatic Uveal Melanoma (OptimUM-10)	Innere Medizin I_711	Preusser Matthias
FA711B1090	A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab As First-Line Treatment in Participants with Unresectable, Locally Advanced or Metastatic Her2-Positive Gastric or Gastroesophageal Junction (GEJ) Cancer	Innere Medizin I_711	Preusser Matthias
FA711C0977	A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination with Venetoclax and Azacitidine in Adult Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy	Innere Medizin I_711	Valent Peter
FA711B1091	A Randomized, Open-Label, Phase 3 Study of UL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigators Choice Therapy in Participants with Relapsed Small Cell Lung Cancer	Innere Medizin I_711	Preusser Matthias
FA711B1079	An Open-Label, Randomized, Controlled Phase-3-Study of Sigvotatug Vedotin in Combination with Pembrolizumab Compared with Pembrolizumab Monotherapy as First-Line-Treatment in Participants with PD-L1 High (greater or equal 50% of Tumor Cells Expressing PD-L1), Locally Advanced, Unresectable, or	Innere Medizin I_711	Preusser Matthias

	Metastatic Non-Small Cell Lung Cancer (BE6A Lung-02)		
FA711A0323	Qualitätssicherung der allogenen Blutstammzelltransplantation in Österreich bei den Hauptindikationen	Innere Medizin I_711	Burgmann Heinz
FA714B4504	OPALISE: A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System when used with the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation	Innere Medizin II_714	Schönbauer Robert
FA714B5305	PROGRESS-ATTR (Definition of disease progression under ATTR-specific treatment with Tafamidis)	Innere Medizin II_714	Nitsche Christian
UE71406026	ARG 2026 (IVUS)	Innere Medizin II_714	Hemetsberger Rayyan
FA714B4921	An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer	Innere Medizin II_714	Gangl Clemens
FA714B5805	The Matrisome in Pulmonary Fibrosis	Innere Medizin II_714	Mayr Manuel
FA714B4309	Eine einarmige, multizentrische Studie mit offener Verlängerung (OLE) zur Beurteilung der langfristigen Sicherheit und Verträglichkeit von Pelacarsen (TQJ230) bei Teilnehmern, die die	Innere Medizin II_714	Krychtiuk Konstantin

	Hauptstudie Lp(a)HORIZON abgeschlossen haben.		
FA714B4922	CA240-0030: A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nabpaclitaxel and Gemcitabine versus Placebo in Combination with Nabpaclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion	Innere Medizin II_714	Gangl Clemens
FA714B2407	Gapless ECG-Monitoring for Stroke Prevention by Atrial Fibrillation detection	Innere Medizin II_714	Pezawas Thomas
FA714B4310	Eine randomisierte, doppelblinde, placebokontrollierte Phase-III-Studie zur Untersuchung der Wirkung von Muvalaplin auf die Verringerung schwerwiegender unerwünschter kardiovaskulärer Ereignisse bei Erwachsenen mit erhöhtem Lipoprotein(a), die bereits ein atherosklerotisches kardiovaskuläres Ereignis hatten oder bei denen das Risiko eines ersten atherosklerotischen kardiovaskulären Ereignisses besteht - MOVE-Lp(a)	Innere Medizin II_714	Krychtiuk Konstantin
FA714B6401	A prospective, single-arm, Phase 4 study to evaluate the course of serum transthyretin (TTR) level with acoramidis in adult patients with variant or wild-type transthyretin amyloidosis with	Innere Medizin II_714	Kammerlander Andreas

	cardiomyopathy (ATTR-CM) previously treated with tafamidis		
FA714B6402	MAGNITUDE: Eine multinationale, multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-3-Studie zur Untersuchung zur Wirksamkeit und Sicherheit von NTLA-2001 bei Teilnehmern mit Transthyretin-Amyloidose mit Kardiopathie (ATTR-CM)	Innere Medizin II_714	Kammerlander Andreas
FA714B5906	Cell-Free DNA Liquid Biopsies for Precision Cardiovascular Medicine	Innere Medizin II_714	Lang Irene
FA714B6302	ZENITH: Eine globale, randomisierte, doppelblinde, placebokontrollierte Phase III Studie zur Bewertung der Wirksamkeit und Sicherheit von Zilebesiran zusätzlich zur Standardbehandlung bei Verringerung schwerwiegender unerwünschter kardiovaskulärer Ereignisse bei erwachsenen Patienten mit unzureichend eingestelltem Bluthochdruck sowie entweder mit etablierter kardiovaskulärer Erkrankung oder hohem Risiko für kardiovaskuläre Erkrankungen	Innere Medizin II_714	Zelniker Thomas
FA714D0516	A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator's choice of chemotherapy in previously treated patients with HER2-	Innere Medizin II_714	Idzko Marco

	expressing recurrent endometrial cancer		
FA714D0517	A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose Ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Participants with Uncontrolled Moderate to Severe Eosinophilic Asthma	Innere Medizin II_714	Idzko Marco
FA714B6108	DCB Study	Innere Medizin II_714	Hemetsberger Rayyan
FA714D0518	A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation.	Innere Medizin II_714	Idzko Marco
FA714B5703	Surgical Bioprosthesis Aortic Valve Replacement Vs. MyVal Balloon-Expandable THV Series in Patients Aged 65 to 75 with Symptomatic Severe Aortic Stenosis	Innere Medizin II_714	Bartko Philipp Emanuel
FA716E1301	A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-controlled, Multicenter Trial to Confirm the Efficacy and Safety of Glepaglutide 10mg Twice-Weekly, Followed by a Long-Term, Open-Label Safety Evaluation in Patients with Short Bowel Syndrome-Intestinal Failure (SBS-IF)	Innere Medizin III_716	Dabsch Stefanie
FA716E1402	A Phase 3b Randomized Multicenter Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered with Tirzepatide in Adult Participants with	Innere Medizin III_716	Reinisch Walter

	Moderately to Severely Active Crohns Disease and Obesity or Overweight		
FA716E1401	A Phase 3b Randomized Multicenter Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered with Tirzepatide in Adult Participants with Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight	Innere Medizin III_716	Reinisch Walter
FA716C1030	A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety of Mezagitamab (TAK-079) in Study Participants with Primary IgA Nephropathy in Combination with Stable Background Therapy	Innere Medizin III_716	Oberbauer Rainer
FW716D0201	PHARmacogenomics of psoriatic Arthritis using multiOmics	Innere Medizin III_716	Bonelli Michael
FA716B0632	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event – MOVE-Lp(a)	Innere Medizin III_716	Kautzky-Willer Alexandra
FA716E1403	A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate	Innere Medizin III_716	Reinisch Walter

	the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis		
FA716E1404	A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohns Disease	Innere Medizin III_716	Reinisch Walter
FA716E1405	A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohns disease	Innere Medizin III_716	Reinisch Walter
FA716E1406	A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled Phase 3, Maintenance Study to Evaluate the Efficacy and Safety of duvakitug in Participants with Moderately to Severely Active Ulcerative Colitis	Innere Medizin III_716	Reinisch Walter
FA716E1701	Alife Vienna - Acute Liver Injury & Failure Exploration in Vienna, Dynamic Trajectories of Organ Dysfunction in Acute Liver Injury (ALI) and Acute Liver Failure (ALF): A Prospective Registry and Biobank Initiative	Innere Medizin III_716	Schneeweiß-Gleixner Mathias Anselm
FA716E1601	PIVKA-II Variabilität bei PatientInnen mit Lebererkrankung unter Vitamin-K-Supplementation	Innere Medizin III_716	Scheiner Bernhard

FA716C1031	A seamless Phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant recipients	Innere Medizin III_716	Oberbauer Rainer
FA716E1801	A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion	Innere Medizin III_716	Schöniger-Hekele Maximilian
FA716B1004	A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants with Classic Congenital Adrenal Hyperplasia	Innere Medizin III_716	Kiefer Florian
FA716E1501	Correlation of differential mucosal gene expression with parameters of disease activity and severity in patients with moderately-to-severely active ulcerative colitis from the LUCENT-URGE study	Innere Medizin III_716	Busslinger Georg
FA716E1901	A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants with Metabolic Dysfunction-Associated Steatotic Liver Disease who are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcome) N1T-MC-MALO,	Innere Medizin III_716	Mandorfer Mattias

	including N1T-MC-TZ01 and N1TMC-RT01		
FA716E1407	Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis	Innere Medizin III_716	Reinisch Walter
FA716E1202	A Phase 3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)	Innere Medizin III_716	Reiberger Thomas
FA716E1203	Investigating the potential clinical impact of different HDV-RNA assays on patient management	Innere Medizin III_716	Reiberger Thomas
FW716D0301	Uncovering novel therapeutic targets in scleroderma	Innere Medizin III_716	Karonitsch Thomas
FA716C0921	A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) (TRANSCEND)	Innere Medizin III_716	Böhmig Georg
FA716C0920	An Open-Label Long-Term Extension Study for Participants from the 299AR301 Felzartamab Study	Innere Medizin III_716	Böhmig Georg

FA716E2001	Realworld, International, Non interventional Study of Guselkumab Persistence in Patients with Crohns Disease and Ulcerative Colitis G FORCE	Innere Medizin III_716	Primas Christian
FW716B0301	Mitochondrial Proline Metabolism in Aging-Induced Sarcopenia.	Innere Medizin III_716	Cikes Domagoj
FW716B0401	AAAgeing	Innere Medizin III_716	Krssak Martin
FA716B1903	Development and standardization of MR-based methods for detecting and evaluating metabolic and structural adaptations of aging muscles to exercise.	Innere Medizin III_716	Krssak Martin
FA716E1204	Test and Feedback Agreement (Phase 3)	Innere Medizin III_716	Reiberger Thomas
FA716E1902	Prospective Observational Study on the Natural History of Alpha-1 Antitrypsin Deficiency and Associated Liver Disease	Innere Medizin III_716	Mandorfer Mattias
FA716E1408	Assessing tissue and blood eosinophils for prognostic value and specific treatment effects of mirikizumab in ulcerative colitis	Innere Medizin III_716	Reinisch Walter
FA716D2505	A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of each of two dose levels of sarilumab in adults with early polymyalgia rheumatica	Innere Medizin III_716	Lechner-Radner Helga
FA716E2101	VISION Validation of Symptom and self-management Information in Inflammatory Bowel Disease A Real-World Observational Study Using a Patient Centric Data Collection Approach	Innere Medizin III_716	Schreiner Philipp
FA716B1904	Simultaneous assessment of muscle perfusion and	Innere Medizin III_716	Krssak Martin

	mitochondrial function in ME/CFS		
FA716B1603	A prospective, randomized, double-blinded, cross-over study investigating the effects of metyrapone treatment on cardio-metabolic outcome parameters and chronobiology in patients with mild autonomous cortisol secretion.	Innere Medizin III_716	Wolf Peter
FA716C3201	Förderung Publikation Case Report Crovalimab 2025	Innere Medizin III_716	Aigner Christof
UE60306002	Prolonged Genocide: The Sterilization and Castration Experiences of Jews in National Socialist Camps	Institut für Ethik, Sammlungen und Geschichte der Medizin_390	Czech Herwig
FA234A0101	Harmonizing Healthcare Data with HL7 FHIR: An ETL Design and Implementation to participate in the Medical Informatics Initiative	IT Services & strategisches Informationsmanagement_230	Düsseldorf Heike
FA781F2401	INNODIA Family & Friends T1D Screening in the Greater Vienna Area	Kinder- und Jugendheilkunde_781	Tauschmann Martin
UE78106033	Gewährleistung der hochqualitativen, interdisziplinären, kombinierten onkologischen Therapie bestehend aus einer Kombination von systemischer Therapie und Partikeltherapie (Protonen und/oder Kohlenstoffionen-Therapie)	Kinder- und Jugendheilkunde_781	Gojo Johannes Salomon
FA781B3901	Augmented Reality and Point of Care Ultrasound in Vascular Access	Kinder- und Jugendheilkunde_781	Küng Erik Simon
FA781B1605	Clinical features and outcomes of children and adults with neurofibromatosis type 1-associated high grade glioma and adults with low grade glioma	Kinder- und Jugendheilkunde_781	Azizi Amedeo

FA781B2902	PAULA: Die Plattform für die Ausbildung an der Universitätsklinik für Kinder- und Jugendheilkunde mit Leitfäden für Assistenzärzt:innen	Kinder- und Jugendheilkunde_781	Bibl Katharina
FA781B4001	SkillTrack: Development of a Digital Competency Logbook for Postgraduate Medical Training at the Medical University of Vienna	Kinder- und Jugendheilkunde_781	Steinbauer Philipp
FA781B5001	CCP iXR-Hub: Innovation and Extended Reality for Pediatric Teaching and Training	Kinder- und Jugendheilkunde_781	Hoffelner Alexander
FA781B3507	A Drug Utilisation Study of Fenfluramine in Europe	Kinder- und Jugendheilkunde_781	Male-Dressler Anastasia
UE78106034	Neue Kombinationstherapien für NF1-assoziierte Tumore	Kinder- und Jugendheilkunde_781	Gojo Johannes Salomon
FA781B3213	Hypothalamic Syndromes in Children and Adolescents with Brain Tumors	Kinder- und Jugendheilkunde_781	Gojo Johannes Salomon
FA781B5101	Evaluating the safety and performance of the MiniLung petite kit in neonatal and pediatric patients with acute respiratory and cardiac failure (PETIT)	Kinder- und Jugendheilkunde_781	Cardona Francesco
FA781F1018	Arrowhead Pharmaceuticals, Inc.	Kinder- und Jugendheilkunde_781	Greber-Platzer Susanne
FA781F2202	Bone and cardiometabolic effects of setmelanotide in children and adolescents with genetic or hypothalamic obesity	Kinder- und Jugendheilkunde_781	Nigmann Charlotte
FA781B3214	CNS-REST Programme	Kinder- und Jugendheilkunde_781	Gojo Johannes Salomon
FA765A1401	Learning to talk about suicidality with adolescents: A digital interview training tool for medical students and clinicians	Kinder- und Jugendpsychiatrie_765	Beris Ayse Nur
FA729A1063	Therapeutic Oligonucleotides Activated by Nucleases: Targeted	Klinische Pharmakologie_729	Zeitlinger Markus

	antibiotics for bacterial infections		
FA729A2003	Use of intravenous fosfomycin in critically ill patients: a retrospective study comparing fosfomycin-containing with colistin-containing regimens for the treatment of Gram-negative infections.	Klinische Pharmakologie_729	Jorda Anselm
FA729A2602	Pharmacokinetic-Pharmacodynamic evaluation of plasma and lung exposure of BV-100	Klinische Pharmakologie_729	Minichmayr Iris
FA729A2603	Enhancing Human Dose Prediction through popPK/PD Modelling in Preclinical Oncology	Klinische Pharmakologie_729	Minichmayr Iris
FA729A1902	In vitro catheter occlusion model for evaluation of rtPA-mediated fibrin clot lysis	Klinische Pharmakologie_729	Miljevic Katarina
FA729A1903	Blood donation to investigate ex vivo blood activation in a hemodialysis circuit	Klinische Pharmakologie_729	Miljevic Katarina
FA729A0179	A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ELA822, an Anti-SIRPy Monoclonal Antibody	Klinische Pharmakologie_729	Jilma Bernd
FA729A1064	Biomimetic antimicrobial peptide inspired by insects to combat multi-drug-resistant Acinetobacter baumannii	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1107	M26-092 - A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination with Venetoclax and Azacitidine in Adult Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to	Klinische Pharmakologie_729	Schörgenhofer Christian

	Receive Intensive Chemotherapy		
FA712A2302	Forschungsvorhaben Stressed out for Cancer	Krebsforschung_712	Csiszar Agnes
FA712A0917	Eine offene, zweiarmige, randomisierte, Phase II Studie mit Elacestrant plus Ribociclib versus Aromataseinhibitor (plus GnRH-Agonist bei prä- und perimenopausalen Frauen und Männern) plus Ribociclib als neoadjuvante Therapie für endokrin-responsivem HER2-negativen Brustkrebs im Frühstadium	Krebsforschung_712	Filipits Martin
FW712A1001	Platinum drugs in the tumor microenvironment	Krebsforschung_712	Heffeter Petra
FW712A1101	Modelling heterogeneous cell clusters and their environment	Krebsforschung_712	Winkler Juliane
FA712A2401	Stratified systemic therapy in HCC: bringing tumour-specific cancer therapy to liver cancer	Krebsforschung_712	Tardito Saverio
FA712A0918	Validating and Expanding the Clinical Utility of a Prognostic Assay for Treatment Deescalation in Breast Cancer	Krebsforschung_712	Filipits Martin
FA712A2205	Spry3 im Brustkrebs	Krebsforschung_712	Sutterlüty Hedwig
FA712A2206	Spry3 im Brustkrebs	Krebsforschung_712	Sutterlüty Hedwig
FA712A2207	Spry3 im Brustkrebs	Krebsforschung_712	Sutterlüty Hedwig
FA712A2208	Spry3 im Brustkrebs	Krebsforschung_712	Sutterlüty Hedwig
FA712A2303	Brustkrebsforschung - Lutz	Krebsforschung_712	Csiszar Agnes
FA712A1504	Brustkrebsforschung - Takacs	Krebsforschung_712	Szakacs Gergely
FA712A2304	Sustainability Award 2026	Krebsforschung_712	Csiszar Agnes

FA793B0127	An interventional Phase 3, open-label, two-cohort study to investigate the efficacy and safety of fosmanogepix in adult patients with invasive mold infections caused by <i>Aspergillus</i> spp., <i>Fusarium</i> spp., <i>Lomentospora prolificans</i> , <i>Mucorales</i> fungi, or other multidrug resistant molds.	Labormedizin_793	Willingner Birgit
FW793A0701	The impact of dyslipidemia on hematopoiesis in the skull	Labormedizin_793	Kiss Mate
FA793B0313	Analytische Validierung der Software LiveGene	Labormedizin_793	Makristathis Athanasios
FA793B0314	Validierungs-Studie der Sepsityper Automation	Labormedizin_793	Makristathis Athanasios
FA793A1909	EvolveBBMRI: Interface MedUni Wien Biobank/Federated Search Platform	Labormedizin_793	Haslacher Helmuth
FA793B0315	Leistungsbewertungsprüfung MycoReal Kit Fungi	Labormedizin_793	Makristathis Athanasios
FA793A2806	Diamond-Blackfan-Anämie	Labormedizin_793	Penninger Josef
FW793A0901	Deciphering the role of IgA immunity in atherosclerosis	Labormedizin_793	Hendrikx Tim
FW793A0801	Advanced particle engineering for precision T cell therapies	Labormedizin_793	Schmidt Ralf
UE61806001	EMBO Postdoctoral Fellowship ALTF 1267-2025	Max Perutz Labs_305	Hein Marco Yannic
FA618A0704	Spendenvereinbarung DBA	Max Perutz Labs_305	Martinez Javier Augusto
FW618A0202	Impact of aSyn Fibrils on human neuronal RNA Metabolism	Max Perutz Labs_305	Hallacli Erinc
FA618A1001	Molecular mechanisms orchestrating the lifecycle of human tRNAs	Max Perutz Labs_305	Nedialkova Danny
FA618A0902	RNA Mechanisms of Resilience and Vulnerability in Aging and Parkinsons Disease	Max Perutz Labs_305	Hallacli Erinc
FA602A0126	Hospital@Home: Person-centered Digital	Medical Data Science_303	Stamm Tanja

	Transformation for Integrated Home Car		
UE66006001	OMOP-based analysis of H2O data	Medical Data Science_303	Duftschnid Georg
FA660A2001	Towards Resilient Reusable Digital Infrastructure for Federated Healthcare Data Analysis (Rwanda, Tanzania)	Medical Data Science_303	Jouned Mhd Adnan
FA605A3805	Bestimmung der mechanischen Eigenschaften von Berlin Heart Mini-VAD Driveline Samples	Medizinische Physik und Biomedizinische Technik_340	Schlöglhofer Thomas
FA605A2407	MRT hautnah 1	Medizinische Physik und Biomedizinische Technik_340	Frass Roberta
FA605A2408	MRT hautnah 2	Medizinische Physik und Biomedizinische Technik_340	Frass Roberta
FA605A4401	Next-Generation Histology with Real-Time Nonlinear Microscopy	Medizinische Physik und Biomedizinische Technik_340	Andreana Marco
FA605A0414	Optical Coherence Tomography Spectrometers	Medizinische Physik und Biomedizinische Technik_340	Drexler Wolfgang
FA605A3806	Summative Usability Evaluation of the CorWave LVAD	Medizinische Physik und Biomedizinische Technik_340	Schlöglhofer Thomas
FA605A4301	This project develops a prototype confocal laser endomicroscopy (CLE) capsule für 3D endoscopic imaging with micro-resolutions. The unique advantage of the invention in its large-area, 3D imaging capabilities, which are not achievable with commercial CLE. Another unique selling point is that these functions are realized without any actuating mechanisms in the capsule, allowing compact capsule design and high design and high-speed imaging. Applications include detection and	Medizinische Physik und Biomedizinische Technik_340	Li Qian

	diagnosis of gastrointestinal cancer.		
FA605A3704	Neurorehabilitation FES 26 - JV	Medizinische Physik und Biomedizinische Technik_340	Nguyen Quang
FA605A3705	Neurorehabilitation FES 26 - HB	Medizinische Physik und Biomedizinische Technik_340	Nguyen Quang
FA605A3807	Optimizing Impella 5.5 Outcomes Through Advanced Data Science: Placement Signal Reliability, Predictive Models for Native Heart Recovery, and Prevention of Adverse Events	Medizinische Physik und Biomedizinische Technik_340	Schlöglhofer Thomas
FA605A2209	Bildqualität 1	Medizinische Physik und Biomedizinische Technik_340	Figl Michael
FA605A2210	Bildqualität 2	Medizinische Physik und Biomedizinische Technik_340	Figl Michael
FA605A4501	Metrology for diagnostic imaging using spectral computed tomography	Medizinische Physik und Biomedizinische Technik_340	Salomon Elisabeth
FW605A0501	Activity of retinal pigment epithelium cells in humans	Medizinische Physik und Biomedizinische Technik_340	Pircher Michael
FA605A3808	ApixiVAD: In Vitro Thrombosis Evaluation Using the HeartMate 3 Snoopy	Medizinische Physik und Biomedizinische Technik_340	Schlöglhofer Thomas
FA605A2803	MRT-Reko	Medizinische Physik und Biomedizinische Technik_340	Schmid Albrecht

FA605A3809	MockLoop - mobiler Herz-Kreislauf Simulator	Medizinische Physik und Biomedizinische Technik_340	Schlöglhofer Thomas
FA605A4601	MORPHEDRON	Medizinische Physik und Biomedizinische Technik_340	Papp Laszlo
FW736A0102	Targeting C19MC miRNAs in ETMR via Antisense LNAs	Neurochirurgie_736	Gabler-Pamer Lisa
FA761A1195	EPICONN APART-USA Fördervereinbarung	Neurologie_761	Berger Thomas
FA761A1194	A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous Prasinezumab in participants with early-stage Parkinson's disease	Neurologie_761	Berger Thomas
FA761A1196	A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy	Neurologie_761	Berger Thomas
UE76106010	Biomarkers, molecular mechanisms and immunological profile of disease activity in adult myasthenia gravis	Neurologie_761	Berger Thomas
FA761A1202	The MJFF LRRK2 Investigative Therapeutics Exchange (LITE) Study	Neurologie_761	Zimprich Alexander
FA761A1198	Gapless ECG-Monitoring for Stroke Prevention by Atrial Fibrillation detection (GEMS-PAF-randomized trial) - A multi-centre, randomized controlled outcome trial	Neurologie_761	Berger Thomas
FA761A1401	Peripheral detection of pathological 4R-tau in PSP using urine	Neurologie_761	Kozala Katarzyna

FA761A1197	Safety and Efficacy of Intravenous Thrombolysis in Patients with Ischemic Stroke on Treatment with Direct Oral Anticoagulants: DO-IT - The DOAC Intravenous Thrombolysis trial	Neurologie_761	Berger Thomas
FW796A0201	MRT-basierte In-vivo-Histologie bei Multipler Sklerose	Neurologie_761	Hametner Simon
FA728A1701	cobas sense TnT hs Patientennahe Tests Analytische Leistungsstudie	Notfallmedizin_728	Schriebl Christoph
FA728A1801	PERCEPTION - SuPER-Early NeuroprognostiCation in ECPR PaTients: Feasibility of AutOmated Pupillometry and Cerebral Near-Infrared Spectroscopy - A Prospective feasibility Study	Notfallmedizin_728	Grafeneder Jürgen
FA737A1603	Entwicklung einer skalierbaren Umsetzungsplattform und von Ansätzen für die zukünftige Anwendung der Body-on-a-Chip-Technologie in militärischen Laboratorien und eine Datensammlung mit realen Gefahrstoffen	Orthopädie und Unfallchirurgie_739	Rothbauer Mario
FA737A1604	Sensor-gestütztes Synovial-Organ-on-Chip für Rheumatoide Arthritis (RA)	Orthopädie und Unfallchirurgie_739	Rothbauer Mario
FA681A0212	Role of Potassium Channels in Sarcoidosis	Pathobiochemie und Genetik_306	Weichhart Thomas
FA608A0337	NANOFEX	Pathobiochemie und Genetik_306	Scheiber-Mojdehkar Barbara
FA608A0338	NANOFEX 2	Pathobiochemie und Genetik_306	Scheiber-Mojdehkar Barbara
FA681A0901	Genome of Europe	Pathobiochemie und Genetik_306	Dremsek Paul
FA681A0506	Nucleolin in Disease	Pathobiochemie und Genetik_306	Steinkellner Hannes

FA681A0507	Nucleolin in disease	Pathobiochemie und Genetik_306	Steinkellner Hannes
FA681A0508	Nucleolin in disease	Pathobiochemie und Genetik_306	Steinkellner Hannes
FW681A0501	Complex organoid cultures as preclinical models for CRC	Pathobiochemie und Genetik_306	Dolznig Helmut
FA681A0214	Metabolic Signaling in Patient-Derived Granuloma Cultures for Diagnosis, Prognosis, and Treatment Monitoring	Pathobiochemie und Genetik_306	Weichhart Thomas
FA681A0213	Monoamine metabolism in fibrotic sarcoidosis	Pathobiochemie und Genetik_306	Weichhart Thomas
FA791A1167	MorningLyte - A Phase III randomized, open-label, international, multicenter, study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti-CD20 mAb plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1048	APART USA	Pathologie_791	Egger Gerda
FA791A4110	An Open label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer	Pathologie_791	Mozayani Behrang
FA791A4111	DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or	Pathologie_791	Mozayani Behrang

	Metastatic HER2-expressing Biliary Tract Cancer		
FA791A4112	A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	Pathologie_791	Mozayani Behrang
FA791A1679	CATALINA-2: A Phase 2, Study Evaluating the Efficacy and Safety of TORL-1-23 In Women in Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A4113	A Blinded, Randomized Phase 2/3 Study of Punitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer	Pathologie_791	Mozayani Behrang
FA791A3507	An Open-Label, Randomized, Controlled Phase 3 Study Of Sigvotatug Vedotin In Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy As First-Line Treatment In Participants	Pathologie_791	Oberndorfer Felicitas

	With Pd-L1 High (50% Of Tumor Cells Expressing Pd-L1), Locally Advanced, Unresectable, Or Metastatic Non-Small Cell Lung Cancer (Be6a Lung-02)		
FA791A3508	CA266-0001: ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Punitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy. Compound: BMS-986545 (BNT327; PM8002)	Pathologie_791	Oberndorfer Felicitas
FA791A3427	Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer	Pathologie_791	Comperat Eva Maria
FA791A2705	A Phase 2/3, Multicenter, Randomized Open-label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors	Pathologie_791	Mazal Peter
FA791A1680	A Phase III Randomized Open-Label Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physicians Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-	Pathologie_791	Bago-Horvath Zsuzsanna

	1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)		
FA791A1049	Gewebsasservierung	Pathologie_791	Kain Renate
FA791A1682	Phase 3, Randomized, Open-label, Multicenter Study of MK-2870 Maintenance With or Without Bevacizumab Versus Standard of Care in Participants With Newly- Diagnosed Advanced HRD- Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse- 021-GOG-3102/ENGOT- ov85)	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1681	WO46069: A TWO-PART, SEAMLESS, MULTICENTER, RANDOMIZED, OPEN-LABEL, ADAPTIVE PHASE II/III STUDY OF THE BLOOD- BRAIN BARRIER PENETRANT RO7771950 VERSUS TUCATINIB, BOTH IN COMBINATION WITH TRASTUZUMAB AND CAPECITABINE, IN PATIENTS WITH PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER, WITH OR WITHOUT CENTRAL NERVOUS SYSTEM METASTASES (BREnnA)	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1050	Immunpathologie	Pathologie_791	Kain Renate

FA791A1683	A Phase III, randomized, multi-site, open-label trial of BNT323/DB 1303 versus investigator's choice of chemotherapy in previously treated patients with HER2-expressing recurrent endometrial cancer	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A3903	A seamless Phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant recipients	Pathologie_791	Kozakowski Nicolas
FA791A0807	3D Tumormodelle Praktika	Pathologie_791	Egger Gerda
FA791A1684	A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)	Pathologie_791	Bago-Horvath Zsuzsanna
FA624A0701	Fc-Engager: A Promising Technology to Induce Antigen-Specific Tolerance	Pathophysiologie, Infektiologie und Immunologie_370	Leitner Judith
FA648A1721	ME/CFS Biobank Austria	Pathophysiologie, Infektiologie und Immunologie_370	Untersmayr-Elsenhuber Eva
FA644A1201	SLORA Sick leave on the rise in Austria	Pathophysiologie, Infektiologie und Immunologie_370	Odor Gergely
FA624A0605	Depleting pathogenic Th2 cells via alarmin receptors	Pathophysiologie, Infektiologie und Immunologie_370	Boucheron Nicole
FA648A2701	Persistent Platelet-Monocyte CrossTalk Underlies Failure to Resolve Inflammation and Symptoms in ME/CFS	Pathophysiologie, Infektiologie und Immunologie_370	Ljungström Ivars Maria

FW623A0402	Mechanisms of metronidazole resistance in Bacteroides	Pathophysiologie, Infektiologie und Immunologie_370	Leitsch David
FW623A0303	OMV-Based Trivalent Vaccine against Chlamydia	Pathophysiologie, Infektiologie und Immunologie_370	Inic-Kanada Aleksandra
FA623A0804	Sand fly-borne diseases in North Macedonia - an integrative approach using stray dogs as sentinels	Pathophysiologie, Infektiologie und Immunologie_370	Kniha Edwin
FA648A1722	Biological evidence and mechanism-based disease classification for the improved diagnosis, prognosis and treatment of ME/CFS (DISCOVER-ME)	Pathophysiologie, Infektiologie und Immunologie_370	Untersmayr-Elsenhuber Eva
FA648A2306	Spatial Omics in Translational Research	Pathophysiologie, Infektiologie und Immunologie_370	Mechtcheriakova Diana
FW625A0501	Dissecting the network of vascular inflammation and thrombosis	Physiologie und Pharmakologie_350	Assinger Alice
FW625A0401	Bacterial EVs drive platelet dysfunction in infection	Physiologie und Pharmakologie_350	Schrottmaier Waltraud
FA641A0908	Rapid peptidomic discovery of uterotonic cyclotides/knottins from Nigerian ethnomedicines with oxytocin-receptor triage as described in the budget of the attached application	Physiologie und Pharmakologie_350	Gruber Christian
FA641A1303	Ligand screening in structure dynamics response (SDR) assay	Physiologie und Pharmakologie_350	Hellinger Roland
FW641A0901	Studying the molecular mechanism of the lysosomal SLC MFSD1	Physiologie und Pharmakologie_350	Roblek Marko
FW641A1001	Positive allosteric modulators of norepinephrine transporter	Physiologie und Pharmakologie_350	Boytssov Danila
FA641A0909	Chasing immunomodulatory peptides from underexplored plants and fungi	Physiologie und Pharmakologie_350	Gruber Christian
FW683A0301	Biophysical properties of organic cation transporter 3	Physiologie und Pharmakologie_350	Schicker Klaus

FW641A0202	Decoding the Molecular Basis of Energy Coupling in SERT	Physiologie und Pharmakologie_350	Stockner Thomas
FA734A0401	Raman spectroscopy for quantitative evaluation of nerves	Plastische, Rekonstruktive und Ästhetische Chirurgie_734	Naghilouye Hidaji Aida
FW734A0301	Establishment of Adult Human Organotypic Spinal Cord Slices	Plastische, Rekonstruktive und Ästhetische Chirurgie_734	Millesi Flavia
FW763A0401	Dopamine and insulin in psychosis: Imaging the effects of intranasal insulin on dopamine transmission	Psychiatrie und Psychotherapie_763	Willeit Matthäus
FA763C1001	"Spezialisierte psychiatrische Mutter-Kind Einheit"	Psychiatrie und Psychotherapie_763	Unger Annemarie
FA763B1601	Prospektive, nicht-interventionelle, multizentrische, einarmige Studie zur Sammlung von Daten über die Anwendung von Daridorexant zur Behandlung von chronischer Insomnie bei erwachsenen Patienten im Versorgungsalltag in Deutschland und Österreich	Psychiatrie und Psychotherapie_763	Bartova Lucie
FA638A0802	Sustainable Participatory Approach for Research Capacities for Malaria	Public Health_380	Erber Astrid Christine
FA646A0709	Evaluation des Stadtmenschen - Gesundheitsbotschafter: innen - Krebsvorsorge für Frauen Projekts	Public Health_380	Grabovac Igor
FA669A0114	Scalable approach to mental illness and self-harm prevention online	Public Health_380	Simon Judit
FW771E0401	AI-Driven Real-time Motion and BO-Field Correction	Radiologie und Nuklearmedizin_771	Motyka Stanislav
FW771D0101	Computational Bone Health Phenotyping in Multiple Myeloma	Radiologie und Nuklearmedizin_771	Langs Georg
FA771E2002	ME/CFS MRI	Radiologie und Nuklearmedizin_771	Haider Lukas
FW771G0301	One Scan, One System	Radiologie und Nuklearmedizin_771	Geist Barbara Katharina

FA771G0299	A Phase 2/3, Multicenter, Randomized Open-label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771D0540	An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer	Radiologie und Nuklearmedizin_771	Wolf Florian
FA771E2301	Prediction of neonatal outcome using advanced MR imaging	Radiologie und Nuklearmedizin_771	Schmidbauer Victor
FA771B0429	Elacestrant and Ribociclib in Ki67-tested endocrine responsive breAst cancer: An open-label, two-arm, randomized, phase II study of elacestrant plus ribociclib vs. AI (plus GnRH agonist in pre-/perimenopausal women and men) plus ribociclib as neoadjuvant therapy for endocrine-responsive HER2-negative early breast cancer	Radiologie und Nuklearmedizin_771	Helbich Thomas
FA771B1908	A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants with Metabolic Dysfunction-Associated Steatotic Liver Disease who are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcome	Radiologie und Nuklearmedizin_771	Attenberger Ulrike

FW771E0501	Understanding weight-loss effects on brain metabolism	Radiologie und Nuklearmedizin_771	Niess Fabian
FA771D0541	A randomized, open label,3-arm Phase 3 study of precentabart tocentecan with or without bevacizumab compared to trifluridine/tipiracil plus bevacizumab in participants with previously treated metastatic colorectal cancer (PROCEADE-CRC-03)	Radiologie und Nuklearmedizin_771	Wolf Florian
FA771G0601	APSIN, Efficacy and safety of adjuvant peptide receptor radionuclide therapy after curative surgery of locoregional limited small intestine neuroendocrine neoplasia - a multi-center, prospective, open-label, two-arm parallel group, randomized, controlled, phase III study	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA733A0204	Contract within the Cooperation Agreement between MUW and Therakos Statement of Work # 1 Foundation and Preparation	Thoraxchirurgie_733	Benazzo Alberto
FA733A0107	ETOP 27-23 ARCH STUDY	Thoraxchirurgie_733	Aigner Clemens
FW733A0201	Personalized platinum drugs for resistant lung cancer	Thoraxchirurgie_733	Schelch Karin
FA733A0305	Cystische Fibrose Register der europäischen CF-Gesellschaft (ECFSR)	Thoraxchirurgie_733	Jaksch Peter
FA727A0625	CA061-1011: A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-targeted NEX-T CAR T Cells, in participants with active SLE (including Lupus Nephritis) with inadequate response to Glucocorticoids and at least two immuno suppressants.	Transfusionsmedizin und Zelltherapie_727	Worel Nina

FA727A0626	A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN)	Transfusionsmedizin und Zelltherapie_727	Müller Antonia Maria Susanne
FA670B0107	The Osteocyte-HO-1 Axis and its Role in Maintaining Skeletal Balance	Universitätszahnklinik_670	Gruber-Kuchler Reinhard
FA670A0201	Study Agreement Guilin Woodpecker Medical Instrument Co., Ltd	Universitätszahnklinik_670	Tur Dino
FA743A0285	Phase 1/2 Study of Intravesical MK-3120 in BCG-Naive or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer	Urologie_743	Shariat Shahrokh
FA743A0801	A Phase II Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Fezolinetant in Patients With Prostate Cancer With Hot Flashes Due to Androgen Deprivation	Urologie_743	Korn Stephan
FA743A0286	A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib versus Cabozantinib in Participants with advanced RCC who experienced disease recurrence during or after prior adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)	Urologie_743	Shariat Shahrokh
FA690A0706	Epidemiologic and genetic pattern of hMPV circulation in relation to RSV before and after the implementation of widespread use of RSV	Virologie_307	Redlberger-Fritz Monika

	vaccines and/or mABs in children and elderly.		
FW690A0102	Neutralization mechanisms of TBEV by antibodies	Virologie_307	Stiasny Karin

Markus Müller

Rektor